3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
62
Nivolumab
40
Ipilimumab
24
trametinib
13
dabrafenib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
binimetinib
9
Cyclophosphamide
8
CTLA-4 Antigen
8
Biopsy
8
encorafenib
7
fludarabine
6
Radiosurgery
6
Cisplatin
6
relatlimab
5
cemiplimab
5
atezolizumab
5
Pemetrexed
5
Introns
5
Interleukin-2
5
tislelizumab
4
lenvatinib
4
fludarabine phosphate
4
durvalumab
4
dostarlimab
4
cobimetinib
4
avelumab
4
Radiotherapy
4
Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Melanoma
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled